News for Sartorius Aktiengesellschaft (SRT3.DE)

The following slide deck was published by Sartorius Aktiengesellschaft in conjunction with their 2025 Q2 earnings call.

Sartorius Aktiengesellschaft (OTCPK:SARTF) Q2 2025 Earnings Conference Call July 22, 2025 7:00 AM ETCompany ParticipantsAlexandra Gatzemeyer - Head of the...

Sartorius Aktiengesellschaft (SARTF) sees a significant year-on-year revenue increase. The company reaffirms its optimistic 2025 financial outlook. E

Sartorius Aktiengesellschaft press release (SARTF): 1H Non-GAAP EPS of €2.44. Revenue of €1.77B (+5.4% Y/Y). The Americas region recorded a gain of 7.1 percent in constant currencies

Sartorius Aktiengesellschaft (OTCPK:SARTF) Q4 2024 Earnings Call January 28, 2025 7:00 AM ETCompany ParticipantsJoachim Kreuzburg - Chief Executive...

Sartorius Aktiengesellschaft press release (SARTF): FY Non-GAAP EPS of €4.05. Revenue of €3.38B (-0.3% Y/Y). Order intake + 10.8 percent, demand increasingly picking

Sartorius Aktiengesellschaft (OTCPK:SARTF) Q3 2024 Earnings Conference Call October 17, 2024 7:00 AM ETCompany ParticipantsJoachim Kreuzburg - ChairmanRené...

Sartorius Aktiengesellschaft (SARTF) reports Q3 GAAP EPS of €0.26 and revenue of €655.4M, a 1.7% decrease year-over-year.

The Longleaf Partners Fund declined -6.31% in the second quarter, compared to the S&P 500 and Russell 1000 Value, which returned 4.28% and -2.17%.

Sartorius Aktiengesellschaft (OTCPK:SARTF) Q1 2024 Earnings Conference Call April 18, 2024 7:00 AM ETCorporate ParticipantsDr.

Sartorius Aktiengesellschaft reported Q1 GAAP EPS of €1.01 and revenue of €819.6M. In Q1, it recorded an increase in order intake of 9.8% in constant currencies.

EQS-Ad-hoc: SARTORIUS AG / Key word: Transaction in Own Shares SARTORIUS AG: Sartorius launches placement of up to 200 million euros of treasury preference shares through accelerated...

Sartorius Aktiengesellschaft (OTCPK:SARTF) Q4 2023 Earnings Call Transcript January 26, 2024 7:00 AM ETCompany ParticipantsDr.

Sartorius Aktiengesellschaft (SARTF) reports FY GAAP EPS of €4.94 and revenue of €3.39B in their latest press release.

Bio-Rad Laboratories' investment returns are expected to be hindered by economic and technical factors. Read why I downgraded BIO stock from Buy to Hold.